2 active not recruiting, 2 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 2 |
Follow Relapsing Multiple Sclerosis (RMS): new trials by email Literature Review of Relapsing Multiple Sclerosis (RMS) trials Research Report on Relapsing Multiple Sclerosis (RMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Ofatumumab approved dose, Ofatumumab new dose - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 196 | 2025-03-13 | 2026-08-10 |
| An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Ublituximab - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Active not recruiting | TG Therapeutics, Inc. | 1100 | 2019-11-18 | 2026-10-30 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 549 | 2017-09-19 | 2021-12-06 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 545 | 2017-08-25 | 2021-12-06 |
ublituximab (3) · teriflunomide (2)
TG Therapeutics, Inc. (3) · Novartis Pharmaceuticals (1)
United States (4) · Belarus (1) · Croatia (1) · Georgia (1) · Poland (1) · Puerto Rico (1) · Russia (1) · Serbia (1) · Ukraine (1)
PMID 36001711, PMID 39512280, PMID 41787239, PMID 42292352, PMID 41697690
2017 (2), 2019 (1)